Abstract
Objective: Review the scientific literature about the Remdesivir’s clinical efficacy as a possible form to treat infected patients with the new coronavirus (SARS-CoV-2). Literature Review: Positive results were observed with the use of Remdesivir in vitro and in vivo against SARS-CoV-2, by inhibiting replication in differents cells cultures, reducing the number of lung lesions and decreasing the functional impairment of lungs in animal models. However, there are divergences in clinical trial outcomes concerning recovery time, chances of clinical improvement, mechanical ventilation time and mortality in patients infected with the new coronavirus who have been treated with this nucleoside analog, making impossible the generalization of the findings. Final considerations: It is essential to carry out more clinical trials with a high specific impact, to better elucidate the clinical efficacy and adverse effects of the drug Remdesivir to be used on patients with COVID-19, analyzing the possible risks and benefits of the antiviral.